Search Within

Madelyn Marie Espinosa Cotton

Formats
  1. Journal Article (9)
  2. Meeting Abstract (3)
  3. Review (3)
  4. Editorial (1)
Groups
  1. Sloan Kettering Institute Postdocs (16)
  2. GSK Faculty (15)
  3. Tow Center for Developmental Oncology (TCDO) (15)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (13)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (13)
  6. Neuroblastoma Service (13)

More Groups

People
  1. Nai-Kong Cheung (13)
  2. Hong-Fen Guo (7)
  3. Marc Ladanyi (3)
  4. Romel Somwar (3)
  5. Sayed Shahabuddin Hoseini (3)
  6. Alison Schram (2)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (4)
  4. 2022 (4)
  5. 2021 (3)
  6. 2020 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (4)
  2. Frontiers in Cell and Developmental Biology (3)
  3. Frontiers in Oncology (2)
  4. Blood Advances (1)
  5. Cancer Discovery (1)
  6. Cancer Research (1)

More Publications

Publishers
  1. Frontiers Media S.A. (5)
  2. Biomed Central Ltd (4)
  3. American Association for Cancer Research (2)
  4. American Society of Hematology (1)
  5. Elsevier Inc. (1)
  6. Hindawi Publishing Corporation (1)

More Publishers

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bispecific antibodies for the treatment of neuroblastoma
    Review

    Espinosa-Cotton, M.; Cheung, N. K. V.
    Pharmacology & Therapeutics (2022)

    Fulltext@MSK | Save
  • Zenocutuzumab, a HER2XHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
    Journal Article

    Schram, A. M.; Odintsov, I.; Espinosa-Cotton, M.; Khodos, I.; Sisso, W. J.; Mattar, M. S.; Lui, A. J. W.; Vojnic, M.; Shameem, S. H.; Chauhan, T.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Immunotherapy and radioimmunotherapy for desmoplastic small round cell tumor
    Review

    Espinosa-Cotton, M.; Cheung, N. K. V.
    Frontiers in Oncology (2021)

    Fulltext@MSK | Save
  • The HER2xHER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
    Meeting Abstract

    Odintsov, I.; Khodos, I.; Espinosa-Cotton, M.; Lui, A. J.; Mattar, M.; Schram, A. M.; Schackmann, R. C.; Lammerts van Bueren, J.; Geuijen, C. A.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia
    Journal Article

    Hoseini, S. S.; Vadlamudi, M.; Espinosa-Cotton, M.; Tran, H.; Feng, Y.; Guo, H. F.; Xu, H.; Cheung, I.; Cheung, N. K. V.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
    Journal Article

    Hoseini, S. S.; Espinosa-Cotton, M.; Guo, H. F.; Cheung, N. K. V.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save